A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-07 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
=== Meat === Fermented meats, sausage, jerky, and corned beef can last many months without refrigeration. Pastirma is a beef product that is often eaten raw in the Middle East and Mediterranean countries. It is made from the hindquarter of beef cattle. Pastirma is a type of intermediate moisture food and can be stored for several months in humid climates. The meat is salted and dried to reduce water activity and increase microbial safety. Additionally, nitrites are added for preservation. The final product has 5% salt and a moisture content between 30-35%.
== Measurement == Molar masses are almost never measured directly. They may be calculated from standard atomic masses, and are often listed in chemical catalogues and on safety data sheets (SDS). Molar masses typically vary between:
In September 1987, Galloway was asked by a journalist about his relationship to a woman during the 1986 War on Want conference on the Greek island of Mykonos. Galloway admitted having an extra-marital affair, saying:I travelled to, and spent time in, Greece with lots of people, many of whom were women, some of whom were known carnally to me. I actually had sexual intercourse with some of the people in Greece. And if the British public and BBC Scotland think that's of interest they are welcome to broadcast it. As a result, Galloway made front-page headlines in the tabloid press at the time. He and his first wife separated that year. In February 1988, the executive committee of his constituency Labour Party passed a vote of no confidence in him by 15 to 8. The constituency's general management committee voted 54-to-44 in favour of the motion a fortnight later on 22 February, although just three of the 25 members in the trade union section supported it. Galloway gained re-selection when challenged by Trish Godman (wife of fellow MP Norman Godman) in June 1989, but failed to get a majority of the electoral college on the first ballot. This was the worst result for any sitting Labour MP who was reselected, but Galloway gained 62% in total in the final vote. Galloway assured his party there would be a "summer of peace and reconciliation" in his acceptance speech, but this did not happen.
Sources: en.wikipedia.org
This is how gallstones form when a small piece of calcium gets coated with either cholesterol or bilirubin and the bile crystallises and forms a gallstone. The main purpose of the gallbladder is to store and release bile, or gall. Bile is released into the small intestine in order to help in the digestion of fats by breaking down larger molecules into smaller ones. After the fat is absorbed, the bile is also absorbed and transported back to the liver for reuse.
The Lombard dukes of Friuli ruled Aquileia and the surrounding mainland territory from Cividale. In 774, Charlemagne conquered the Lombard duchy and made it into a Frankish one with Eric of Friuli as duke. In 787, Charlemagne named the priest and master of grammar at the Palace School of Paulinus II, the new patriarch of Aquileia. The patriarchate, despite being divided with a northern portion assigned to the pastoral care of the newly created Archbishopric of Salzburg, would remain one of the largest dioceses. Although Paulinus resided mainly at Cividale, his successor Maxentius considered rebuilding Aquileia. However, the project never came to fruition. While Maxentius was patriarch, the pope approved the Synod of Mantua, which affirmed the precedence of the mainland patriarch of Aquileia over the patriarch of Grado. However, material conditions were soon to worsen for Aquileia. The ruins of Aquileia were continually pillaged for building material. And with the collapse of the Carolingians in the tenth century, the inhabitants would suffer under the raids of the Magyars. By the eleventh century, the patriarch of Aquileia had grown strong enough to assert temporal sovereignty over Friuli and Aquileia. The Holy Roman Emperor gave the region to the patriarch as a feudal possession. However, the patriarch's temporal authority was constantly disputed and assailed by the territorial nobility.
== Climate == Based on the Köppen climate classification, Endless Chain Ridge is located in a subarctic climate with cold, snowy winters, and mild summers. Winter temperatures can drop below −20 °C with wind chill factors below −30 °C. Precipitation runoff from Endless Chain Ridge drains west to the Sunwapta River, or east into the Maligne River, both of which are tributaries of the Athabasca River.
Sources: en.wikipedia.org
Adropin is a protein encoded by the energy homeostasis-associated gene ENHO in humans and is highly conserved across mammals. The biological role of adropin was first described in mice by Andrew Butler's team. They identified it as a protein hormone (hepatokine) secreted from the liver, playing a role in obesity and energy homeostasis. The name "Adropin" is derived from the Latin words "aduro" (to set fire to) and "pinguis" (fat). Adropin is produced in various tissues, including the liver, brain, heart, and gastrointestinal tract. In animals, adropin regulates carbohydrate and lipid metabolism and influences endothelial function. Its expression in the liver is controlled by feeding status, macronutrient content, as well as by the biological clock. Liver adropin is upregulated by estrogen via the estrogen receptor alpha (ERα). In humans, lower levels of circulating adropin are linked to several medical conditions, including the metabolic syndrome, obesity, and inflammatory bowel disease. and inflammatory bowel disease. The brain exhibits the highest levels of adropin expression, In the brain, adropin has been shown to have a potential protective role against neurological disease, where it may play a protective role against neurological diseases, brain aging, cognitive decline, and acute ischemia. as well as following acute ischemia. The orphan G protein-coupled receptor GPR19 has been proposed as a receptor for adropin.
== Organizational structure == The Commission consists of the chairman and other members appointed by the President of the Republic of India. Usually, the Commission consists of 9 to 11 members, including the chairman. Every member holds office for a term of six years or until he attains the age of sixty-five years, whichever is earlier. The terms and conditions of service of the chairman and members of the commission are governed by the Union Public Service Commission (Members) Regulations, 1969. The chairman and any other member of the commission can submit their resignation at any time to the President of India. They may be removed from their office by the President of India on the ground of misbehavior (only if an inquiry of such misbehavior is made and upheld by the Supreme Court) or if he is adjudged insolvent, or engages during the term of office in any paid employment outside the duties of their office, or in the opinion of the president unfit to continue in office because of the infirmity of mind or body.
== Research == Lectka's research expertise lies in areas of catalysis in synthetic and mechanistic organic chemistry. He has contributed to the discovery of metal-catalyzed amide isomerization, and metal-catalyzed alkane fluorination, along with the development of first practical method for the catalytic, asymmetric synthesis of β-lactams. During his studies at Cornell University from 1986 until 1991, Lectka focused on the design, synthesis, and study of stable carbocations with three-center, two-electron [C-H-C] bonds; and discussed the chemical shift of central hydrogen by the progressively smaller bond angles. He also studied alkane protonolysis leading to stoichiometric hydrogen evolution, MO theory of three-center bonding, and titanium promoted carbonyl coupling reactions. He investigated the reproducibility problems caused by the age, history and source of titanium chloride and introduced an optimized procedure that provided reproducibly high yields. Lectka continued his research on MO theory and photoelectron spectroscopy during his fellowship at Heidelberg University. As a fellow at Harvard University, he focused on the asymmetric catalysis of the Diels-Alder reaction using bisoxazoline and bisimine Lewis acid complexes. After joining Johns Hopkins University in 1994, Lectka conducted research on new catalytic and asymmetric reactions, along with enantioselective reactions of imines, quinones and amides catalyzed by chiral Lewis acids and nucleophiles; such as catalytic, asymmetric synthesis of β-lactams; and nonnatural α- and β-amino acids.
== Signs and symptoms == The typical screening process for sleep apnea involves asking patients about common symptoms such as snoring, witnessed pauses in breathing during sleep, and excessive daytime sleepiness. There is a wide range in presenting symptoms in patients with sleep apnea, from being asymptomatic to falling asleep while driving. Due to this wide range in clinical presentation, some people are not aware that they have sleep apnea and are either misdiagnosed or ignore the symptoms altogether. A current area requiring further study involves identifying different subtypes of sleep apnea based on patients who tend to present with different clusters or groupings of particular symptoms. OSA may increase the risk of car crashes and work-related injuries due to sleep fragmentation from repeated arousals during sleep. If OSA is not treated, it results in excessive daytime sleepiness and oxidative stress from the repeated drops in oxygen saturation, and people are at increased risk of other systemic health problems, such as diabetes, hypertension or cardiovascular disease. Subtle manifestations of sleep apnea may include treatment refractory hypertension and cardiac arrhythmias and over time as the disease progresses, more obvious symptoms may become apparent. Due to the disruption in daytime cognitive state, behavioral effects may be present. These can include moodiness, belligerence, as well as a decrease in attentiveness and energy. These effects may become persistent, leading to depression.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.